Records 1-30 (of 1091 Records) |
Query Trace: all[original query] |
---|
BNT162b2 and mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 and Variants in the Urban Underserved Population. Weng Chien-Hsiang, et al. Rhode Island medical journal (2013) 2023 0 0. (1) 26-28 ![]() ![]() ![]() ![]() |
Entity and relation extraction from clinical case reports of COVID-19: a natural language processing approach. Raza Shaina, et al. BMC medical informatics and decision making 2023 0 0. (1) 20 ![]() |
Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers. Ellingson Katherine D, et al. Emerging infectious diseases 2023 0 0. (3) ![]() ![]() ![]() ![]() |
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023 RL Gelles et al, MMWR, January 25, 2023 ![]() ![]() ![]()
The SARS-CoV-2 Omicron BA.2-related sublineage XBB.1.5 is gaining predominance nationwide. Vaccine effectiveness against XBB and XBB.1.5 is unknown.
Using spike (S)-gene target presence as a proxy for BA.2 sublineages, including XBB and XBB.1.5, during December 2022–January 2023, the results showed that a bivalent mRNA booster dose provided additional protection against symptomatic XBB/XBB.1.5 infection for at least the first 3 months after vaccination in persons who had previously received 2–4 monovalent vaccine doses.
|
An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines. Al-Sheboul Suhaila A, et al. Vaccines 2023 0 0. (1) ![]() ![]() ![]() ![]() |
Pilot Study for Immunogenicity of SARS-CoV-2 Vaccine with Seasonal Influenza and Pertussis Vaccines in Pregnant Women. Shen Ching-Ju, et al. Vaccines 2023 0 0. (1) ![]() ![]() ![]() ![]() |
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors. Zsichla Levente, et al. Viruses 2023 0 0. (1) ![]() |
Optimized Quantification of Intrahost Viral Diversity in SARS-CoV-2 and Influenza Virus Sequence Data. Roder A E, et al. bioRxiv : the preprint server for biology 2023 0 0. ![]() ![]() |
[Analysis on the household secondary attack rates of the SARS-CoV-2 Delta variant and the associated factors]. Ma T, et al. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 2023 0 0. (1) 8-14 ![]() ![]() ![]() ![]() |
Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort. Nguyen Vincent Grigori, et al. International journal of epidemiology 2023 0 0. ![]() ![]() ![]() ![]() |
Applications of social media and digital technology in COVID-19 vaccination: a scoping review. Zang Shujie, et al. Journal of medical Internet research 2023 0 0. ![]() ![]() ![]() |
Variations in COVID-19 impacts by social vulnerability in Philadelphia, June 2020-December 2022 KM Strelau et al, MEDRXIV< January 14, 2023 ![]()
90.4% of Philadelphians (n = 1,430,153) live in neighborhoods classified as socially vulnerable, based on scoring above the national median score on the social vulnerability index. COVID-19 incidence, hospitalization, and mortality rates were significantly elevated in the more vulnerable communities, with p < 0.05, p < 0.005, and p < 0.001, respectively. The relative risks of COVID-19-related incidence, hospitalization, and death, comparing the more vulnerable neighborhoods to the less vulnerable neighborhoods, were 1.11 (95%CI: 1.10-1.12), 2.07 (95%CI: 1.93-2.20), and 2.06 (95%CI: 1.78-2.38), respectively.
|
COVID-19 in Latin America: A Snapshot in Time and the Road Ahead. LaRotta Jorge, et al. Infectious diseases and therapy 2023 0 0. ![]() ![]() ![]() ![]() ![]() ![]() |
Lethality risk markers by sex and age-group for COVID-19 in Mexico: a cross-sectional study based on machine learning approach. Rojas-García Mariano, et al. BMC infectious diseases 2023 0 0. (1) 18 ![]() ![]() ![]() ![]() |
Incentivizing COVID-19 vaccination among racial/ethnic minority adults in the United States: $209 per dose could convince the hesitant. Chen Kevin, et al. Health economics review 2023 0 0. (1) 4 ![]() ![]() ![]() |
Severe COVID-19 Infection in Type 1 and Type 2 Diabetes During the First Three Waves in Sweden. Edqvist Jon, et al. Diabetes care 2023 0 0. ![]() ![]() ![]() |
COVID-19 international experience in paediatric patients with congenital heart disease. Yeh Mary J, et al. Heart (British Cardiac Society) 2023 0 0. ![]() ![]() ![]() |
Evaluation of clinical severity according to primary infection variants in patients with suspected SARS-CoV-2 reinfection. Hwang Myung-Jae, et al. Epidemiology and health 2023 0 0. e2023007 ![]() ![]() ![]() ![]() ![]() |
A traveling SARS-CoV-2 laboratory as part of a pandemic response among vulnerable Brazilian populations. Elias Maria Carolina et al. BMC public health 2023 1 (1) 15 ![]() ![]() ![]() ![]() ![]() |
Comparison of humoral immunogenicity in solid organ transplant recipients after third-dose mRNA vaccine with homologous or heterologous schedules: An observational study. Kang Ji-Man, et al. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2023 0 0. 105374 ![]() ![]() ![]() ![]() |
Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Tan Sophia T, et al. Nature medicine 2023 0 0. ![]() ![]() ![]() ![]() ![]() |
SARS-CoV-2 seroprevalence in children worldwide: A systematic review and meta-analysis. Naeimi Reza, et al. EClinicalMedicine 2023 0 0. 101786 ![]() ![]() ![]() ![]() |
Interpretable generalized neural additive models for mortality prediction of COVID-19 hospitalized patients in Hamadan, Iran. Moslehi Samad, et al. BMC medical research methodology 2022 0 0. (1) 339 ![]() ![]() ![]() |
Is targeting angiotensin-converting enzyme 2 (ACE2) a prophylactic strategy against COVID-19? Li Jing, et al. Bioscience trends 2022 0 0. (6) 459-461 ![]() ![]() ![]() ![]() ![]() |
Blood Transfusion, All-Cause Mortality and Hospitalization Period in COVID-19 Patients: Machine Learning Analysis of National Health Insurance Claims Data. Lee Byung-Hyun, et al. Diagnostics (Basel, Switzerland) 2022 0 0. (12) ![]() ![]() ![]() |
Clinical Application of Detecting COVID-19 Risks: A Natural Language Processing Approach. Bashir Syed Raza, et al. Viruses 2022 0 0. (12) ![]() ![]() |
Myopericarditis following both BNT162b2 and NVX-CoV2373. Ahmad Saima, et al. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2022 0 0. (1) 109 ![]() ![]() ![]() |
Clinical severity of Omicron sub-variants BA.1, BA.2 and BA.5 in a population-based cohort study in British Columbia, Canada. Russell Shannon L, et al. Journal of medical virology 2022 0 0. ![]() ![]() ![]() |
Race, inequalities, and burden of COVID-19 in the USA G Bisbas, The Lancet Infectious Diseases, December 21, 2022 ![]() |
Infectious diseases genomic surveillance capacity in the Caribbean: A retrospective analysis of SARS-CoV-2 MA Ber Lucien et al, Lancet Regional Health, December 19, 2022 ![]() ![]()
As of August 6, 2022, the number of SARS-CoV-2 sequences from the Caribbean are underrepresented with only 40,190 (1.07%) of the over 3.76 million documented cases sequenced, which is further exacerbated by a disparity based not only on the country's income but also on its political status (sovereign country versus dependent or integrated) and accessibility to sequencing technologies.
|
Disclaimer: Articles listed in the Public Health
Knowledge Base are selected by the CDC Office of Public Health
Genomics to provide current awareness of the literature and news.
Inclusion in the update does not necessarily represent the views of
the Centers for Disease Control and Prevention nor does it imply
endorsement of the article's methods or findings. CDC and DHHS assume
no responsibility for the factual accuracy of the items presented. The
selection, omission, or content of items does not imply any
endorsement or other position taken by CDC or DHHS. Opinion, findings
and conclusions expressed by the original authors of items included in
the update, or persons quoted therein, are strictly their own and are
in no way meant to represent the opinion or views of CDC or DHHS.
References to publications, news sources, and non-CDC Websites are
provided solely for informational purposes and do not imply
endorsement by CDC or DHHS.
- Page last reviewed:Jul 25, 2022
- Page last updated:Jan 31, 2023
- Content source: